alexa Identification Of A New Prognostic Signatures And Therapeutic Targets For HER2+ And Triple Negative Breast Cancer Using Subtype-specific Mouse Models
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

International Conference & Exhibition on Cancer Science & Therapy
15-17 August 2011 Las Vegas, USA

Eldad Zacksenhaus
Toronto General Research Institute – University Health Network, Canada
ScientificTracks Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.16
Abstract
HER2+ and Triple-Negative Breast Cancers (TNBC) represent highly aggressive subtypes. HER2+ BC is commonly treated with chemotherapy plus anti-HER2 drugs, such as Herceptin. Drug resistance, high cost and side effects limit the use and benefits of anti-HER2-therapy worldwide. There is therefore great interest in an effective prognostic predictor and novel therapeutic targets for HER2+ breast cancer. We identified MMTV-Her2/Neu mammary tumor-initiating cells (TICs) and showed that non-adherent tumorspheres can be used as surrogate for TICs (Can Res. 2007, Clin Can Res. 2009). Using improved conditions, we have further enriched Her2/Neu TICs to a frequency of 1/20-1/40. A 17-gene TIC-specific signature derived from differentially expressed genes in TICs versus non-TICs predicts survival in multiple human HER2+ BC cohorts with hazard ratios of over 8, and can be used to stratify HER2+ patients for anti-HER2 therapy (submitted). Using a lentiviral shRNA screen, we also identified several kinases required for Her2/Neu tumorsphere growth, for which no previous requirement for their function in HER2+ BC has been described (in progress). TNBCs often contain loss-of-function mutations/alterations in the tumor suppressors RB1, p53 and Pten. We showed that conditional deletion of Rb in mammary stem cells/bipotent progenitors led to tumors that clustered with luminal-B or TNBC. The latter contained mutations in p53. Combined deletions of Rb and p53 led exclusively to TNBC (J. Clin Invest. 2010, Cell Cycle, 2011). Similarly, inactivation of Pten in mammary epithelium induced diverse tumor types, whereas combined deletion of Pten and p53 led to TNBC-like tumors (in progress). Drug and shRNA screens have identified several agents/targets that specifically kill Rb/p53, Pten/p53 mutant TNBC as well as human TNBC lines but not immortalized mammary epithelial cells (in progress).
Biography

Dr. Eldad Zacksenhaus earned his PhD at the University of Toronto in Molecular Genetics on the cloning of UBE1, and postdoctoral training at the Hospital for Sick Children on the tumor suppressor RB. He is senior scientist at University Health Network and Associate Professor of Medicine, University of Toronto. His research is focused on tumor suppressors, in particularly Rb, breast cancer, cancer stem cells and targeted therapy for HER2 and TNBC (JCI, 2010, JCB, 2010, Cancer Res. 2010, Autophagy, 2011, PLoS One, 2011, Cell Cycle 2011). He‘s a co-organized of the “International RB Symposium” Nov. 17-18, 2011, Toronto, Canada.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords